Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (submit ≥45 days before activity start)
Funding Amounts: No fixed minimum/maximum for general educational grants; Advocacy for Impact Grants (up to $50,000 USD per project)
Summary: Supports independent, evidence-based educational initiatives for healthcare professionals, patient organizations, and patients in rare disease areas (ATTR amyloidosis, AHP, PH1).